What question did this study set out to answer?

To evaluate the adverse drug reactions (ADRs) associated with botulinum toxin type A (BoNT‐A) using the FDA Adverse Event Reporting System (FAERS) data.

June 14, 2026Journal of Cosmetic DermatologyOpen Access

Adverse Drug Reaction Study of Botulinum Toxin‐A in the Real World

View Full Paper

Ask AI

Bookmark

Authors

JGJiaxu GuHong Kong University of Science and Technology YSYue SunShantou University KCK ChenPeking University Shenzhen Hospital

Discussion

Member takes

Implication

Randomized trial evaluates adverse drug reactions of botulinum toxin-A, indicating the need for enhanced safety measures.

Key Points

To evaluate the adverse drug reactions (ADRs) associated with botulinum toxin type A (BoNT‐A) using the FDA Adverse Event Reporting System (FAERS) data.
Analyzed 155,449 reports related to BoNT‐A from the FAERS database (2004–2025).
Conducted disproportionality analyses using ROR, PRR, BCPNN, and MGPS algorithms.
Evaluated time‐to‐onset and system organ class distributions to identify high‐risk ADR signals.
A biphasic pattern of ADR onset was observed, with an initial peak within 30 days post-injection and a second peak beyond 360 days.
Most reported SOCs included general disorders (33.22%), injury and procedural complications (16.81%), and nervous system disorders (11.16%).
Common ADR signals included eyebrow ptosis, botulism, and facial paresis, particularly among females (87.8% of cases).

Cite This Study

Gu et al. (2026) studied this question.

synapsesocial.com/papers/6a2e47f9b1cc60ccdea8c5be https://doi.org/10.1111/jocd.70990

View Full Paper

Ask AI

Bookmark

Adverse Drug Reaction Study of Botulinum Toxin‐A in the Real World

Discussion

Member takes

Implication

Key Points

Cite This Study

Adverse Drug Reaction Study of Botulinum Toxin‐A in the Real World

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider